Christopher Hill
Equibles does not estimate personal net worth.
Get an email with a short summary when Adaptimmune Therapeutics PLC publishes a filing, an earnings call transcript or a press release.
Get ADAPY alertsAbout Christopher Hill
Christopher Hill is recorded as CFO at Adaptimmune Therapeutics PLC (ADAPY) since September 10, 2025. Adaptimmune Therapeutics PLC reported in an 8-K filed September 8, 2025 that Christopher Hill was appointed Chief Financial Officer, effective September 10, 2025. Adaptimmune Therapeutics PLC is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Adaptimmune Therapeutics PLC includes Adrian Rawcliffe (CEO and Board Member), David M. Mott (Chairman), William Bertrand (COO) and 7 others.
“On September 6, 2025, Adaptimmune Limited, a subsidiary of Adaptimmune Therapeutics plc (the "Company"), entered into a consulting agreement with CJH Financial Limited (the "Consulting Agreement") providing for the engagement of Christopher Hill as the Company's Chief Financial Officer ("CFO") effective from September 10, 2025.”
Affiliation history
-
Current
2025-09-10–present
Company network
Leadership on record at Adaptimmune Therapeutics PLC
- Adrian Rawcliffe CEO, Board Member
- David M. Mott Chairman
- William Bertrand COO
- Ali Behbahani Board Member
- Andrew Allen Board Member
- Andrew Allen, MD, PhD Board Member
- Andrew R. Allen Board Member
- Dr Priti Hegde Board Member
- Garry E. Menzel Board Member
- Garry Menzel Board Member